EPA-Registered Ionic Silver Disinfectant Effective Against 2009 H1N1 Flu Strain

PURE Bioscience Praises FDA’s Actions to Squelch Unregistered Claims for Silver-Based Products

• Press Release
• Source: PURE Bioscience
• On 8:27 am EDT, Tuesday October 27, 2009

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE - News), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains. PURE Bioscience’s SDC disinfectant also meets the recommendations established by the U.S. Centers for Disease Control (CDC) for infection control of H1N1 in both home and healthcare settings.

Related Quotes

Symbol	Price	Change
PURE	1.91	-0.04

{"s" : "pure","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“President Obama this weekend declared the H1N1 pandemic a national emergency. We are proud to offer government, business and the public a powerful and effective weapon in the battle against H1N1,” said Michael L. Krall, President and CEO of PURE Bioscience.

“Our ionic silver disinfectant formula quickly and completely eliminates bacteria, fungi and viruses, including 2009 H1N1, while using astoundingly small amounts of silver -- only 30 parts per million. We continue to invest heavily to develop, patent and obtain regulatory clearances for SDC, including our EPA-registered hard surface disinfectant,” added Krall.

Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, SDC disinfectant is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products. SDC disinfectant has been registered by the EPA specifically for use on children’s toys, cribs, high chairs and other sensitive areas of the home as well as for use on hard surfaces in multitudes of environments, including hospitals, schools and offices.

“Unsubstantiated and unapproved claims to kill H1N1 should not be tolerated in the marketplace, and we applaud the FDA’s recent warnings against companies that are seeking to profit from this pandemic using false claims about their products,” Krall said. “Influenza, including H1N1, continues to be a serious and growing public health threat. Consumers should only trust products that have been reviewed and approved by appropriate regulatory agencies. In addition, regarding environmental antimicrobials in particular, consumers should read labels carefully to understand the differences between products that disinfect versus those that only sanitize.”

Products registered by the EPA as “disinfectants” provide complete elimination of specifically claimed microorganisms; “sanitizers” merely reduce the number of microorganisms.

PURE Bioscience’s broad spectrum SDC-based disinfectant completely eliminates bacteria, viruses and fungi and is registered with the EPA under the trade name Axen30®. Independent lab studies and resulting EPA-registered claims document that PURE’s disinfectant kills resistant strains of bacteria, including MRSA (Methicillin-resistant Staphylococcus aureus), CA-MRSA, PVL-MRSA and VRE (Vancomycin resistant Enterococcus faecium) in just 2 minutes. In addition, SDC-based disinfectant provide a 30-second kill time on Pseudomonas aeruginosa and Salmonella enteric and a 24-hour residual kill on standard indicator bacteria. Important viral efficacy claims for PURE’s disinfectant include a 3-minute kill against Human Corona virus (SARS surrogate) and Rotavirus and a 10-minute kill against Norovirus, Human Influenza A and Avian Influenza A (Bird Flu). In addition, SDC- disinfectant is odorless, colorless, non-corrosive, non-flammable and is compatible with other disinfecting and cleaning chemicals.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Investor Contact:
Bibicoff + MacInnis, Inc.
Terri MacInnis, Dir. of Investor Relations
818-379-8500
terri@bibimac.com
or
PURE Media Contact:
Gutenberg Communications
Michael Gallo, 212-239-8594
mgallo@gutenbergpr.com